You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石四藥集團(02005.HK):阿比多爾列入新型冠狀病毒肺炎診療方案(試行第六版)
格隆匯 02-19 16:33

格隆匯2月19日丨石四藥集團(02005.HK)公佈,集團產品阿比多爾和利巴韋林被中國國家衞生健康委員會於2020年2月18日列入新型冠狀病毒肺炎診療方案(試行第六版)。根據該診療方案,阿比多爾和利巴韋林被用於"一般治療"的抗病毒藥物。

集團擁有在中國生產阿比多爾原料藥和製劑之領先公司,及集團的阿比多爾膠囊已准入22個省市防控疫情產品儲備目錄或防控藥品綠色通道。於公告刊發之時,阿比多爾膠囊已准入27個省市防控疫情產品儲備目錄或防控藥品綠色通道。阿比多爾作為廣譜抗病毒藥物,在此次抗疫中發揮了很好作用,獲得了醫療機構的廣泛認可,為集團拓展該產品奠定良好的市場基礎。公司相信阿比多爾將成為集團未來業務拓展的主導產品之一。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account